Skip to content
Inciteful Med

Long-Term Monitoring and Living Well with FMF

Last updated:

While Familial Mediterranean Fever (FMF) is a lifelong condition, it is highly manageable. Regular blood tests, especially Serum Amyloid A (SAA) and CRP, are essential to detect 'silent' inflammation between attacks and protect your kidneys from long-term damage.

Key Takeaways

  • • Regular blood tests for SAA and CRP are critical to monitor for silent inflammation between FMF attacks.
  • • Keeping your SAA levels below 10 mg/L helps protect your kidneys from a serious complication called amyloidosis.
  • • Urine tests should be done every 6 to 12 months to check for protein, which is an early warning sign of kidney stress.
  • • A comprehensive care team for FMF typically includes a rheumatologist, nephrologist, genetic counselor, and mental health professional.
  • • Psychological stress triggers attacks in most FMF patients, making mental health and anxiety management a medical priority.

A diagnosis of Familial Mediterranean Fever (FMF) marks the beginning of a lifelong journey of health management. While the condition cannot be “cured,” it can be exceptionally well-managed. With the right care team and a proactive monitoring plan, most people with FMF live full, active, and healthy lives [1][2].

Your Monitoring “Radar”

Because FMF can cause “silent” or subclinical inflammation (inflammation you cannot feel), regular testing is the only way to ensure your body is truly protected [3][4].

The Blood Test Roadmap

  • Serum Amyloid A (SAA): This is your most important “radar” [5]. SAA is a protein that rises during inflammation and is the direct cause of kidney damage (amyloidosis) [6][7]. Your doctor will check this when you are not having an attack to make sure your level is low (typically below 10 mg/L) [8][9].
  • C-Reactive Protein (CRP) and ESR: These are standard markers of general inflammation [10][11]. High levels between attacks suggest that your colchicine dose may need to be adjusted [4][12].
  • CBC (Complete Blood Count): Used to monitor your white blood cell count and ensure your body is responding well to medication [13].

The Urine Test: Protecting Your Kidneys

  • Urinalysis / Microalbuminuria: At least every 6 to 12 months, you should provide a urine sample to check for protein [5][14]. Protein in the urine is the “first alarm” that the kidneys might be under stress from inflammation [15][5].

Building Your Care Team

FMF affects the whole body, so your medical team may include several specialists:

  • Rheumatologist: The “quarterback” of your care who manages your diagnosis and medication [16][17].
  • Nephrologist (Kidney Specialist): Essential if there is any sign of protein in your urine or if you have high-risk genetic mutations (like M694V) [18][11].
  • Genetic Counselor: Can help you understand your specific mutations and what they mean for your family or future children [19][12].
  • Mental Health Professional: Chronic illness is stressful. Since psychological stress is a major trigger for FMF attacks (affecting 75% of patients), managing anxiety is a medical priority [20][21].

Living Well: Beyond the Attacks

Living with FMF is about more than just surviving the flares; it’s about thriving between them.

  • Track Your Trends: Keep a “flare diary” to record the dates, symptoms, and potential triggers of your attacks [20]. This data is invaluable for your doctor to see if your treatment is working.
  • Address the Fatigue: Many patients experience lingering fatigue between attacks [22]. If you never feel “100%,” discuss this with your doctor, as it may be a sign of low-level inflammation that needs attention [4].
  • Adherence is Freedom: It may feel burdensome to take a pill every day when you feel fine, but that daily dose is what allows you to stay fine [23][12].

With modern medicine and consistent monitoring, FMF is no longer a “mysterious” or “hopeless” condition. You have the tools to stay ahead of the inflammation and protect your future [24][3].

Frequently Asked Questions

How often should I test my SAA and CRP levels with FMF?
You should have your Serum Amyloid A (SAA) and C-Reactive Protein (CRP) tested regularly, even when you feel well. These tests help your doctor detect silent inflammation and adjust your medication to prevent long-term organ damage.
What is the target SAA level for someone with FMF?
The typical target for Serum Amyloid A (SAA) is below 10 mg/L. Keeping your SAA below this level between attacks is crucial for protecting your kidneys from a serious complication called amyloidosis.
Why do I need to see a kidney specialist for FMF?
A nephrologist can help monitor your kidney health, especially if you have high-risk genetic mutations like M694V or if a urine test shows protein. Untreated inflammation from FMF can lead to serious kidney complications over time.
Is it normal to feel tired between FMF attacks?
Lingering fatigue between attacks is common, but it can also be a sign of low-level, silent inflammation. If you never feel fully recovered between flares, you should discuss this with your doctor to see if your treatment needs adjusting.
How does stress affect Familial Mediterranean Fever?
Psychological stress is a major trigger for FMF attacks, affecting up to 75 percent of patients. Working with a mental health professional to manage anxiety and stress is considered an important part of your overall medical care.

Questions for Your Doctor

  • • How often should I have my SAA and CRP levels checked while I am feeling well to monitor for 'silent' inflammation?
  • • What is my 'target' SAA level (e.g., below 10 mg/L), and how will we adjust my treatment if it stays high?
  • • Should I have a baseline appointment with a nephrologist to monitor my kidney health long-term?
  • • If I am still experiencing significant fatigue or 'mini-flares' between my major attacks, does that mean my inflammation isn't fully controlled?
  • • Can you recommend a mental health professional who has experience working with patients with chronic or autoinflammatory conditions?

Questions for You

  • • How do I feel in the days or weeks between my attacks? Am I completely 'normal,' or do I still feel tired or achy?
  • • Do I have a system for tracking my flares (e.g., an app or a calendar) to show my doctor how often they really happen?
  • • How much does the unpredictability of an attack affect my daily planning or my anxiety levels?
  • • Am I comfortable with my current care team, or do I feel like I need more specialized support for my kidneys or my mental health?

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    [Familial Mediterranean fever – an important disease in a globalised world].

    Wekell P, Karlsson A, Fasth A, Berg S

    Lakartidningen 2016; (113()).

    PMID: 27551868
  2. 2

    Arterial stiffness in Familial Mediterranean Fever: correlations with disease-related parameters and colchicine treatment.

    Sgouropoulou V, Stabouli S, Trachana M

    Clinical rheumatology 2019; (38(9)):2577-2584 doi:10.1007/s10067-019-04601-6.

    PMID: 31127463
  3. 3

    Serum Amyloid A Level in Egyptian Children with Familial Mediterranean Fever.

    Lofty HM, Marzouk H, Farag Y, et al.

    International journal of rheumatology 2016; (2016()):7354018 doi:10.1155/2016/7354018.

    PMID: 28070191
  4. 4

    Familial Mediterranean Fever: an unusual cause of liver disease.

    Maggio MC, Castiglia M, Corsello G

    Italian journal of pediatrics 2019; (45(1)):121 doi:10.1186/s13052-019-0712-0.

    PMID: 31533789
  5. 5

    Amyloidosis and Glomerular Diseases in Familial Mediterranean Fever.

    Siligato R, Gembillo G, Calabrese V, et al.

    Medicina (Kaunas, Lithuania) 2021; (57(10)) doi:10.3390/medicina57101049.

    PMID: 34684086
  6. 6

    French practical guidelines for the diagnosis and management of AA amyloidosis.

    Georgin-Lavialle S, Savey L, Buob D, et al.

    La Revue de medecine interne 2023; (44(2)):62-71 doi:10.1016/j.revmed.2022.12.004.

    PMID: 36759076
  7. 7

    Secondary amyloidosis associated with heroin use and recurrent infections - A case report.

    Mani D

    Annals of medicine and surgery (2012) 2019; (37()):38-41 doi:10.1016/j.amsu.2018.11.013.

    PMID: 30581568
  8. 8

    The Value of Serum Amyloid A Levels in Familial Mediterranean Fever to Identify Occult Inflammation During Asymptomatic Periods.

    Çakan M, Karadağ ŞG, Tanatar A, et al.

    Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases 2021; (27(1)):1-4 doi:10.1097/RHU.0000000000001134.

    PMID: 31524848
  9. 9

    Concordance between CRP and SAA in familial Mediterranean fever during attack-free period: A study of 218 patients.

    Stankovic Stojanovic K, Hentgen V, Fellahi S, et al.

    Clinical biochemistry 2017; (50(4-5)):206-209 doi:10.1016/j.clinbiochem.2016.11.008.

    PMID: 27838405
  10. 10

    Intima media thickness as an early predictor of atherosclerosis in Egyptian children with familial Mediterranean fever.

    Mahmoud SSE, Ismail NA, Farag YM, et al.

    Archives of medical sciences. Atherosclerotic diseases 2018; (3()):e106-e111 doi:10.5114/amsad.2018.77545.

    PMID: 30775599
  11. 11

    Familial mediterranean fever and long-term cardiovascular disease burden.

    Magen E, Aamar S, Merzon E, et al.

    The American journal of medicine 2026; doi:10.1016/j.amjmed.2026.01.006.

    PMID: 41520806
  12. 12

    A survey of resistance to colchicine treatment for French patients with familial Mediterranean fever.

    Corsia A, Georgin-Lavialle S, Hentgen V, et al.

    Orphanet journal of rare diseases 2017; (12(1)):54 doi:10.1186/s13023-017-0609-1.

    PMID: 28302131
  13. 13

    Can RDW be used as a screening test for subclinical inflammation in children with FMF? Is RDW related to MEFV gene mutations?

    Parmaksız G, Noyan ZA

    Clinical rheumatology 2023; (42(1)):197-202 doi:10.1007/s10067-022-06358-x.

    PMID: 36103024
  14. 14

    Long-term follow-up of paediatric MEFV carriers.

    Makay B, Gülez N

    Clinical rheumatology 2018; (37(6)):1683-1687 doi:10.1007/s10067-017-3883-3.

    PMID: 29101676
  15. 15

    Red Cell Distribution Width (RDW) as a Marker of Subclinical Inflammation in Children with Familial Mediterranean Fever.

    Marzouk H, Mostafa N, Khalifa I, et al.

    Current rheumatology reviews 2020; (16(4)):298-303 doi:10.2174/1573397116666200312142709.

    PMID: 32164513
  16. 16

    Gray zone in the spectrum of autoinflammatory diseases: familial Mediterranean fever accompanying periodic fever, aphthous stomatitis, pharyngitis, and adenitis syndrome: single-center experience.

    Konte EK, Haslak F, Yildiz M, et al.

    European journal of pediatrics 2023; (182(12)):5473-5482 doi:10.1007/s00431-023-05209-4.

    PMID: 37777601
  17. 17

    A retrospective analysis of 7 cases of familial mediterranean fever.

    Ogita C, Matsui K, Kisida D, et al.

    Nihon Rinsho Men'eki Gakkai kaishi = Japanese journal of clinical immunology 2017; (40(1)):21-27 doi:10.2177/jsci.40.21.

    PMID: 28539550
  18. 18

    Heterozygous MEFV Mutation Leading to Renal Failure: A Case Study.

    El Gazzane S, Ichane A, Nahi C, et al.

    Global pediatric health 2024; (11()):2333794X241274752 doi:10.1177/2333794X241274752.

    PMID: 39219559
  19. 19

    Presentation of a new mutation in FMF and evaluating the frequency of distribution of the MEFV gene mutation in our region with clinical findings.

    Arpacı A, Doğan S, Erdoğan HF, et al.

    Molecular biology reports 2021; (48(3)):2025-2033 doi:10.1007/s11033-020-06040-y.

    PMID: 33738724
  20. 20

    Factors triggering familial mediterranean fever attacks, do they really exist?

    Parlar K, Ates MB, Onal ME, et al.

    Internal and emergency medicine 2024; (19(4)):1007-1013 doi:10.1007/s11739-024-03576-w.

    PMID: 38488998
  21. 21

    An Autoethnographic Account of Familial Mediterranean Fever: A Turkish Patient's Discovery of Spiritual Meaning.

    Yuksel C

    Journal of religion and health 2025; (64(5)):3875-3896 doi:10.1007/s10943-025-02253-2.

    PMID: 39870951
  22. 22

    Fatigue in pediatric patients with familial Mediterranean fever.

    Özdel S, Özçakar ZB, Cakar N, et al.

    Modern rheumatology 2018; (28(6)):1016-1020 doi:10.1080/14397595.2018.1427459.

    PMID: 29322855
  23. 23

    Non-adherence to colchicine treatment is a common misevaluation in familial Mediterranean fever

    Tekgöz E, Çolak S, Çınar Fİ, et al.

    Turkish journal of medical sciences 2021; (51(5)):2357-2363 doi:10.3906/sag-2102-328.

    PMID: 33957721
  24. 24

    IL1-blocking therapy in colchicine-resistant familial Mediterranean fever.

    Köhler BM, Lorenz HM, Blank N

    European journal of rheumatology 2018; (5(4)):230-234 doi:10.5152/eurjrheum.2018.18036.

    PMID: 30501849

This page provides educational information about managing Familial Mediterranean Fever (FMF). It does not replace professional medical advice, and you should always consult your rheumatologist about your specific monitoring plan.

Stay up to date

Get notified when new research about Familial Mediterranean fever is published.

No spam. Unsubscribe anytime.